Therapeutic | Tafasitamab |
Target | CD19 |
Heavy Chain | EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS |
Light Chain | DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | MorphoSys HuCAL Phage Display;XmAb Engineering Technology |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | MorphoSys, The Ohio State University Comprehensive Cancer Center, Xencor |
Conditions Approved | na |
Conditions Active | Diffuse large B cell lymphoma, Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma |
Conditions Discontinued | na |
Notes |